Combined Neural Inactivation of Suppressor of Cytokine Signaling-3 and Protein-Tyrosine Phosphatase-1B Reveals Additive, Synergistic, and Factor-Specific Roles in the Regulation of Body Energy Balance
OBJECTIVE The adipokine hormone leptin triggers signals in the brain that ultimately lead to decreased feeding and increased energy expenditure. However, obesity is most often associated with elevated plasma leptin levels and leptin resistance. Suppressor of cytokine signaling (SOCS)-3 and protein-tyrosine phosphatase 1B (PTP-1B) are two endogenous inhibitors of tyrosine kinase signaling pathways and suppress both insulin and leptin signaling via different molecular mechanisms. Brain-specific inactivation of these genes individually in the mouse partially protects against diet-induced obesity (DIO) and insulin resistance. The aim of this study was to investigate possible genetic interactions between these two genes to determine whether combined reduction in these inhibitory activities results in synergistic, epistatic, or additive effects on energy balance control.
RESEARCH DESIGN AND METHODS We generated mice with combined inactivation of the genes coding for SOCS-3 and PTP-1B in brain cells, examined their sensitivity to hormone action, and analyzed the contribution of each gene to the resulting phenotype.
RESULTS Surprisingly, the Nestin-Cre mice used to mediate gene inactivation displayed a phenotype. Nonetheless, combined inactivation of SOCS-3 and PTP-1B in brain revealed additive effects on several parameters, including partial resistance to DIO and associated glucose intolerance. In addition, synergistic effects were observed for body length and weight, suggesting possible compensatory mechanisms for the absence of either inhibitor. Moreover, a SOCS-3–specific lean phenotype was revealed on the standard diet.
CONCLUSIONS These results show that the biological roles of SOCS-3 and PTP-1B do not fully overlap and that targeting both factors might improve therapeutic effects of their inhibition in obesity and type 2 diabetes.
Obesity is a major risk factor for insulin resistance and type 2 diabetes as well as for cardiovascular diseases. Although identification of the adipokine hormone leptin (1) accelerated progress in understanding mechanisms leading to obesity and associated pathologies, much remains to be discovered. Leptin acts on various brain regions including the hypothalamus, ventral tegmental area, and hindbrain (2–10) and regulates energy homeostasis by triggering decreased food consumption and increased energy expenditure. Unfortunately, circulating leptin levels are elevated in most obese humans, and treatment of these patients with leptin was unsuccessful (11,12). Most obesity is associated with central leptin resistance (13) that may result from defects in leptin transport across the blood-brain barrier (14–17) or inflammatory responses in the mediobasal hypothalamus secondary to overnutrition (18,19). Resistance may also result from dysregulation of the leptin receptor intracellular signaling pathway, which prevents appropriate transduction of the leptin signal.
Suppressor of cytokine signaling (SOCS)-3 and protein-tyrosine phosphatase 1B (PTP-1B) suppress cytokine signaling pathways, including the leptin pathway (20–23). Interestingly, the Socs-3 gene is a target for signal transducer and activator of transcription (STAT) 3, which is a crucial mediator of leptin signaling (24). SOCS-3 levels are increased after leptin injection and in mice with diet-induced obesity (DIO) (16,25–28). Chronic activation of the leptin pathway generates a negative-feedback regulatory loop that is believed to alter central leptin signaling in DIO. Hypothalamic PTP-1B levels are also modulated by chronic leptin administration, inflammation, and high-fat diet (HFD) feeding (23,29–32).
Genetic inactivation of the Socs-3 or Ptpn1 (PTP-1B) genes in mouse brain, like whole-body Socs-3 haploinsufficiency or Ptpn1 knockout, leads to enhanced leptin sensitivity and resistance to DIO (33–37). However, possible interactions between the two genes have not been explored. In a system where both genes are inactivated, absence of genetic interaction is expected to be revealed by the addition of the effects generated by the absence of either gene. In contrast, evidence of genetic interaction may be invoked if there is a deviation from such additive effects: this includes synergistic and dominant epistatic effects. In addition, combined inactivation of both genes may reveal new pathways in which both SOCS-3 and PTP-1B play a regulatory role. We therefore decided to investigate possible interactions between Socs-3 and Ptpn1 by generating mice with combined gene inactivation in neural progenitor cells using Nestin-Cre mice. Despite a surprising metabolic phenotype displayed by the Nestin-Cre mice, inactivation of both genes in brain revealed additive effects on most parameters studied. Interestingly, synergistic effects were observed for body length and weight, and some factor-specific phenotypes were also revealed.
RESEARCH DESIGN AND METHODS
Generation of Nestin-Cre;Ptpn1lox/lox;Socs-3lox/lox mice.
Socs-3lox mice were obtained from Dr. Yoshimura and Ptpn1lox mice from Drs. Bence, Kahn, and Neel (35,38). Mice were backcrossed more than six times on a C57BL/6 (Jackson Laboratories) background. Nestin-Cre mice were from Jackson Laboratory (strain no. 377). Details of the breeding strategy can be found in the online appendix (available at http://diabetes.diabetesjournals.org/cgi/content/full/db10-1436/DC1). Animal protocols were approved by the institutional animal care and use committee.
Nestin-Cre (n = 7), floxed (n = 15), Socs-3 (n = 9), Ptpn1 (n = 10), and double-mutant (n = 13) mice were fed a diet containing 45% kcal from fat and 35% kcal from carbohydrates (Research Diets no. D12451) starting at 6 weeks of age. Body weight was measured weekly. Fat mass was measured by EchoMRI (Echo Medical Systems) after 13 weeks on the diet. Oxygen consumption, heat production, and locomotor activity were measured using a Comprehensive Lab Animal–Monitoring System (CLAMS; Columbia Instruments) over 48 h, following a 2-day acclimation period. Ambulatory activity was determined by infrared beam breaks along the x- and y-axes. Food intake was manually measured over 2 consecutive days from single-caged animals after a period of habituation. Mice were killed after 21–30 weeks on the diet.
Blood was collected from tail nicks in the morning between 0800 h and 1000 h for fed measurements. For studies on the HFD, mice were food deprived for 6 h prior to bleeding in the afternoon. Total plasma insulin-like growth factor (IGF)-1 (Diagnostics Systems Laboratories), leptin, and insulin (CrystalChem) were assayed by enzyme-linked immunosorbent assays.
Glucose and insulin tolerance tests.
For glucose tolerance tests, mice were fasted overnight (15–16 h) and intraperitoneally injected with glucose (1 mg/g body wt). For insulin tolerance tests, mice were fasted for 6 h prior to intraperitoneal injections with insulin (0.5 mU/g body wt Humulin R; Eli Lilly).
Leptin sensitivity tests.
Standard diet–fed mice were single housed and habituated to handling for 5 days prior to injections. Mice and food were weighed everyday at 0900 h. Measurements for the last 3 days before injections were averaged and used as baseline values. Saline was intraperitoneally administered for 3 days, followed by mouse recombinant leptin (A.F. Parlow, National Hormone and Peptide Program) twice daily for 3 days (0900 h and 1800 h; dose, 0.75 μg/g; total daily dose, 1.5 μg/g).
Immunohistochemistry for phosphorylated STAT3 (pSTAT3) (Tyr 705; Cell Signaling Technology) was performed on free-floating sections. Overnight-fasted mice were intraperitoneally injected with leptin (3 μg/g) or saline (PBS) and transcardially perfused with 10% formalin under deep anesthesia 3 h after injections. DAB (diaminobenzidine) was used for revelation and hematoxylin for counterstaining. Imaging was carried out on an Axio Imager.A1 microscope (Zeiss), processed with Adobe Photoshop software, and analyzed with MacBiophotonics Image J (National Institutes of Health).
Genetic interaction was tested by two-way ANOVA when a significant difference was found by a t test between double mutants and Nestin-Cre mice. In the absence of interaction, contribution of each gene to the double knockout phenotype is displayed (two-way ANOVA). In the presence of interaction, differences between single mutants and Nestin-Cre mice were tested by one-way ANOVA and displayed. All results are expressed as means ± SE. Tests were performed using GraphPad Prism (Graphpad, San Diego, CA).
Nestin-Cre mice have a metabolic phenotype.
Surprisingly, the Nestin-Cre mice in our study had consistently smaller body weight and length than floxed mice on the standard diet (online appendix Fig. S1A and S1B). In addition, Nestin-Cre mice had higher adiposity and circulating leptin levels than floxed mice (online appendix Fig. S1C and S1D). Nestin-Cre mice were also less tolerant to glucose challenge while slightly more sensitive to insulin administration than floxed mice (online appendix Fig. S1E and S1F and supplementary results).
On an HFD, Nestin-Cre mice gained less weight than floxed mice over time (online appendix Fig. S2A). Body fat content and circulating leptin levels were not significantly different between the two genotypes after 13 weeks on the HFD (Fig. S2B and S2C). Nestin-Cre mice maintained a greater sensitivity to insulin than floxed mice that became insulin resistant and had lower basal circulating insulin levels (Fig. S2D and S2E). However, both genotypes became similarly glucose intolerant (Fig. S2F). In light of such a considerable metabolic phenotype, we used Nestin-Cre mice as the control line for our studies with Socs-3/Ptpn1 mice in order to control for the effect of the Nestin-Cre transgene.
Combined inactivation of Socs-3 and Ptpn1 reveals synergistic effects on body size.
Brain-specific combined gene inactivation was confirmed in double-mutant mice using real-time quantitative PCR (online appendix Fig. S3). Analysis of growth of mice deficient for either SOCS-3 or PTP-1B or both in brain revealed that double mutants had significantly lower weight than single mutants and Nestin-Cre mice after 7 weeks on the standard diet (Fig. 1A). Socs-3 mutants were lighter than Ptpn1 mutants and Nestin-Cre mice across several weeks. However, body weight curves of Ptpn1 mutants and Nestin-Cre mice were similar. Interestingly, Socs-3 and Ptpn1 genes interact in a synergistic manner: the effect observed with combined deletions was larger than the sum of the effects of each gene taken independently (Fig. 1A, note f). Thus, on a Socs-3–null background, central inactivation of Ptpn1 affects body weight homeostasis.
The substantially lower weight of double-mutant mice was associated with a shorter body length (Fig. 1B). As for body weight, both gene deletions contributed synergistically to this phenotype. In line with their smaller size, double mutants had the lowest circulating IGF-1 levels (Fig. 1C). The low body weight of the double mutants might be attributed entirely to their short length. However, double mutants had significantly lower BMI (Fig. 1D). This suggests that their body composition is substantially altered.
Double mutants have low adiposity on the standard diet because of a lack of brain SOCS-3.
Compared with Nestin-Cre mice, fat mass at 19 weeks was similarly reduced in Socs-3 and double mutants (Fig. 2A). Normalization to body weight (Fig. 2B) or to body length using fat mass index (fat mass/height squared) (Fig. 2C) led to the same observation. A two-way analysis indicates that the low adiposity of double knockout mice is attributed to the absence of brain SOCS-3, whereas the absence of PTP-1B does not contribute to this phenotype. In addition, lean mass was significantly reduced only in double mutants (Fig. 2A). This was also true when normalized to body length (not shown). In addition to reduced fat mass, this is likely to contribute to their low BMI.
Various fat depots were dissected from 7- to 8-month-old animals and weighed. Visceral fat pads (retroperitoneal, perirenal, and gonadal), but not subcutaneous pads, were significantly reduced in double mutants compared with Nestin-Cre mice (Fig. 2D). At that age, both gene deletions contributed to this phenotype, although absence of SOCS-3 had the main effect. In addition, whereas visceral fat pads were significantly larger than subcutaneous pad in Nestin-Cre and single-mutant mice (Fig. 2E), both depots accounted for similar fractions of total dissected pads in double mutants. This suggests that the relative contribution of fat depots to body weight is changed when both Socs-3 and Ptpn1 genes are deleted in the brain.
In line with lower adiposity, leptin levels were reduced in double mutants, and this was mainly attributed to the absence of SOCS-3 (Fig. 3A). However, neither food intake nor ambulatory activity was different from Nestin-Cre mice (Fig. 3B and C). A trend toward higher energy expenditure (oxygen consumption and generated heat per kilogram body weight) was observed but did not reach significance (Fig. 3D and E). Respiratory quotient was unchanged among mutants (Fig. 3F).
Double mutants gain less weight on an HFD than Nestin-Cre mice.
Both brain Socs-3– and Ptpn1-null mice were reported to be protected against DIO (34,35). We therefore examined response to DIO in our cohorts. Double mutants weighed significantly less than Nestin-Cre mice until week 14 on the HFD (Fig. 4A). Despite the weight effect of the Nestin-Cre transgene, we found that double mutants gained significantly less weight than Nestin-Cre mice over the first 10 weeks on the HFD (P < 0.05; comparing Nes and N-P1/S3-KO curves). Both gene deletions contributed to this subtle reduction in weight gain (two-way analysis at week 10: interaction: NS, P1: P = 0.01, S3: P = 0.01). This protection was nonetheless not total since double mutants still gained substantial weight on the HFD over those on the standard diet (Fig. 4B).
Fat mass was measured after 13 weeks on the HFD (Fig. 4C). Double mutants had significantly lower adiposity than Nestin-Cre mice, and deletion of Ptpn1 accounted for this phenotype (two-way ANOVA). However, after 5–7 months on the HFD, no significant difference in fat pad weights was detected between genotypes (Fig. 4D). This may reflect a ceiling effect. Nonetheless, visceral fat pads were smaller than subcutaneous depots in double mutants, whereas the opposite was observed for Nestin-Cre and Ptpn1 mutants (Fig. 4E), in line with our observations on the standard diet.
Double mutants have high energy expenditure on the HFD.
After 11–13 weeks on the HFD, double mutants had low circulating leptin levels compared with Nestin-Cre mice. This phenotype was attributed to both Ptpn1 and Socs-3 deletions (Fig. 5A). Although food intake and ambulatory activity were not changed (Fig. 5B and C), oxygen consumption and heat generated were significantly increased in double-mutant mice (Fig. 5D and E). In both cases, deletion of Socs-3 accounted for most of the variance (two-way ANOVA). Respiratory quotient was not changed (Fig. 5F). All together, our data indicate that double-mutant mice are more resistant to DIO than Nestin-Cre mice and that this resistance may be attributed to increased energy expenditure.
Leptin sensitivity is enhanced in mice lacking brain SOCS-3 and PTP-1B.
The finding of normal food intake and normal to high energy expenditure of double-mutant mice in the context of low circulating leptin levels suggest that leptin signaling is enhanced in these mice. Therefore, we examined sensitivity to recombinant leptin.
Upon repeated daily injections of recombinant leptin, 27- to 31-week-old single and double knockout mice demonstrated a greater body weight loss than Nestin-Cre mice on the second day of treatment (Fig. 6A, day 5). After 3 days of injections, only double mutants presented a significant body weight loss compared with Nestin-Cre mice. Two-way ANOVA tests indicate that combined gene deletions had similar additive effects. However, in contrast to body weight, we were unable to detect a significant difference between mutant and Nestin-Cre mice in leptin-induced anorexia (Fig. 6B).
STAT3 plays a role in propagating the leptin signal and is phosphorylated upon leptin binding to its receptor. Under basal conditions, there were more cells in hypothalamic arcuate nucleus (ARN) with high levels of pSTAT3 in double mutants (Fig. 6C), an effect accounted for by Ptpn1 deletion (two-way ANOVA). Upon leptin injections, only Socs-3 and double mutants presented a significant increase in the number of ARN cells with high levels of pSTAT3.
The ventromedial nucleus of the hypothalamus (VMN) is another important leptin-responsive brain region involved in body weight and glucose homeostasis (4,39). As in the ARN upon leptin action, the number of leptin responsive pSTAT3+ cells in the VMN was higher in Socs-3 and double mutants, and absence of Socs-3 accounted for the phenotype displayed by double mutants.
Despite differences in STAT3 activation, no significant differences were detected in transcript levels of anorexigenic Pomc1 and orexigenic Agrp and Npy genes in the ARN between the genotypes, either basally or upon leptin administration in 7- to 11-month-old mice (not shown). This is in accordance with the absence of significant differences in daily food intake in our cohorts.
Glucose homeostasis is improved by combined brain deletions of SOCS-3 and PTP-1B.
Because increased adiposity and leptin resistance are associated with insulin resistance leading to diabetes, we evaluated glucose homeostasis in our double mutants, both on the standard diet and HFD.
Glycemia was not different between genotypes on chow diet (Fig. 7A). However, double mutants had significantly lower blood glucose levels after 11–13 weeks on the HFD than Nestin-Cre mice. Socs-3 and Ptpn1 deletions had similar additive effects on lowering glucose levels (Fig. 7B). In addition, circulating insulin levels were lower in double mutants on standard diet and a trend toward low insulin levels on the HFD was observed (Fig. 7C and D). Interestingly, brain specific Socs-3 deletion accounted for the low insulinemia displayed by double mutants (Fig. 7C, two-way ANOVA). All together, these observations suggest that double mutants are more insulin sensitive than controls on both diets.
Glucose tolerance tests revealed that on both diets, area under the curve was significantly smaller for double mutants compared with Nestin-Cre mice (Fig. 7E and F). On the standard diet, the effect of Ptpn1 deletion did not quite reach significance and Socs-3 deletion had the main effect. On HFD, overnight-fasted glucose levels were lower for Ptpn1 (P < 0.01) and double mutants (P < 0.001) before injections (Fig. 7F). Both gene deletions had additive effects on improving glucose tolerance, although Socs-3 contributed the most.
Sensitivity to insulin injections was improved for double mutants on both diets as well. On the standard diet, both genes contributed equally to this effect (Fig. 7G). On the HFD, double-mutant mice had significantly lower basal glucose levels than Nestin-Cre mice (P < 0.001). Deletion of Socs-3 gene did not quite significantly affect insulin tolerance, while Ptpn1 deletion had a main effect (two-way ANOVA) (Fig. 7H). Hence, insulin sensitivity of double mutants on HFD is improved to an extent comparable to brain Ptpn1 mutants, while on the standard diet it reflects the similar additive protective effects of each deletion.
Although obesity is typically associated with high circulating leptin levels, most obese animals and humans maintain elevated energy intake. Furthermore, in obese rodents, resistance to exogenous leptin led to the concept of leptin resistance (13). Thus, approaches that increase leptin sensitivity may provide insights into developing novel therapies for obesity and associated diseases. SOCS-3 and PTP-1B act as endogenous inhibitors of cytokine signaling pathways. Importantly, both factors suppress leptin as well as insulin signaling, which makes them potential targets for type 2 diabetes treatment. Indeed, PTP-1B inhibitors are under development or testing in antidiabetic clinical trials (40,41).
To evaluate the possibility that Socs-3 and Ptpn1 genes might interact in the regulation of body weight and glucose homeostasis, mice with combined gene deletions in the brain were generated. In the course of these experiments, the Nestin-cre mice, used to mediate gene inactivation, appeared to have an intrinsic metabolic phenotype including reduced body weight and length in the context of increased adiposity on the standard diet but less weight gain on the HFD than floxed controls. These intrinsic phenotypes may mask some of the phenotypes previously reported by brain-specific single-gene mutants. For example, both brain single mutants were reported to be resistant to DIO compared with floxed siblings (34,35). However, in our hands, single mutants were not better protected against DIO than Nestin-Cre mice (one-way analysis), whereas single mutants were when compared with floxed siblings (not shown). Hence, phenotypes caused by presence of the Nestin-Cre transgene are likely to mask subtle phenotypes caused by absence of either SOCS-3 or PTP-1B in our Nestin-Cre–mediated knockout mice.
Phenotypic discrepancies were observed for single mutants between the pioneer studies with the brain Ptpn1 or Socs-3 knockout (34,35) and ours. Those discrepancies may result from use of different strains of Cre-expressing mice (see above), from diet compositions (different in all three studies), and from genetic background differences. Indeed, marked differences in feeding, energy expenditure, and response to DIO have been reported between C57BL/6 and 129 genetic backgrounds (42).
The finding of a phenotype of Nestin-Cre mice suggests that these mice must be used with caution in metabolic studies. Although our data does not address whether the above described phenotypes are attributed to disruption of gene sequences at the locus of the transgene insertion or to potential Cre toxicity in particular cell types, it has previously been shown that high Cre activity levels are toxic to neural stem/progenitor cells (43).
Despite the metabolic phenotype of Nestin-Cre mice, combined inactivation in brain of Ptpn1 and Socs-3 revealed synergistic interactions and additive effects, which ranged from the addition of similar effects to primary and gene-specific effects. No antagonistic functions, some of which may lead to negation of an effect, were revealed. Importantly, the current study was the first direct comparison of the roles of SOCS-3 and PTP-1B in siblings or closely related single knockout mice. The contribution of each gene to the phenotypes observed in double mutants is summarized in Table 1.
Body length and body weight were the only parameters that revealed synergism between SOCS-3 and PTP-1B actions. Combined brain deletions led to a short body length phenotype. We examined aspects of the growth hormone axis: double mutants had the lowest IGF-1 levels and trended to the lowest growth hormone levels (not shown). This suggests that the growth hormone/IGF-1 axis is centrally affected by loss of SOCS-3 and PTP-1B. Both SOCS-3 and PTP-1B bind to and suppress signaling through the growth hormone and IGF-1 receptors (44–47). Both growth hormone and IGF-1 exert a feedback onto hypothalamic neurons that leads to suppression of growth hormone pituitary secretion. Double mutants might have increased hypothalamic sensitivity to circulating growth hormone and IGF-1, leading to a reduction in growth hormone which in turn leads to reduced IGF-1 secretion and small body size.
This synergism suggests that when only one factor is deleted, compensatory mechanisms substitute to maintain linear growth, and these mechanisms cannot be sustained when both proteins are absent. As we did not observe any change in PTP-1B or SOCS-3 expression in Socs-3 and Ptpn1 mutants, respectively, compared with Nestin-Cre mice (Fig. S3), possible compensatory mechanisms do not involve upregulation of expression of the other inhibitor in single mutants.
In addition, both SOCS-3 and PTP-1B suppress signaling through receptor-associated Janus kinase 2 (JAK2) and tyrosine kinase receptors, although they have different modes of action: SOCS-3 can interact with and block JAK2 activity, promote degradation of insulin receptor substrate proteins and receptor complex via its SOCS box, and block access to specific cytokine receptor tyrosine residues, whereas PTP-1B is an endoplasmic reticulum–associated enzyme that dephosphorylates and inactivates these same partners, probably following endocytosis of the ligand receptor complex (21–24). We might speculate that in absence of SOCS-3, fewer cytokine receptor complexes may be targeted for degradation by the proteasome, thereby increasing the pool of recycled receptors and leading to increased signal transduction. In the absence of PTP-1B, internalized receptor complexes might remain phosphorylated and hence active for a longer period of time. Combined absence of SOCS-3 and PTP-1B might then result in multiplicative effects of absence of each factor on stability and activity of the same target molecule. However, one might then wonder why this synergistic effect is only detected for body length and not for adiposity or other parameters. Further investigation is needed to understand the molecular basis of this synergy.
Most phenotypes displayed by the double knockout mice resulted from the addition of the phenotypes displayed by the single knockout mice. For example, inactivation of both genes contributed to the partial protection against DIO and associated hyperglycemia and glucose intolerance displayed by double mutants. Protection against DIO was associated with higher energy expenditure, suggesting that the sympathetic tone may be stimulated in absence of both factors.
Additive effects may underlie independent functions, indicating that the biological roles of SOCS-3 and PTP-1B do not fully overlap. These factors may act on different downstream pathways that contribute to the same phenotypes or on the same pathways but on different targets. However, we cannot rule out that some dominant epistatic effects might not have been revealed because of the difficulty in obtaining large cohorts of single- and double-conditional knockout mice. Interestingly, some phenotypes displayed by the double mutants are largely attributed to the absence in the brain of either SOCS-3 or PTP-1B. For instance, Ptpn1 deletion transiently has a main effect on adiposity levels on HFD.
In contrast, deletion solely of Socs-3 is responsible for low adiposity and low insulin levels on the standard diet. Although mice with single deletions had same levels of food consumption and energy expenditure, Socs-3 mutants were leaner than Ptpn1 mutants with lower circulating leptin levels. This suggests that leptin sensitivity is enhanced in Socs-3 mutants. However, both single mutants lost similar amount of weight upon repeated leptin administration, indicating comparable leptin sensitivity. Two hypotheses involving either a decrease in energy input or an increase in energy output, might account for such discrepancies.
First, the low power of our CLAMS study may prevent a thorough assessment of energy expenditure. Alternatively, the underlying difference may be beyond the limit of detection of currently available equipment. In fact, upon HFD feeding that challenges metabolic regulatory mechanisms, Socs-3 deletion accounts for most of the double knockout increase in energy expenditure, suggesting enhanced energy expenditure in Socs-3 mutants. In addition, a difference in body weight between single mutants is already detectable at 8 weeks on the standard diet and increases at a slow rate afterward. As energy expenditure was assessed at 6–7 months, the older age may prevent the detection of a small change in energy expenditure. Increased energy expenditure may result from increased sympathetic activity. Low insulin levels of Socs-3 mutants might then be a consequence of high sympathetic activity, which was shown to affect the bioactivity of a bone-derived insulin segretagogue (48). In turn, low insulin levels might contribute to reduced adipose mass.
Second, our study does not address possible differences in intestinal absorption. Possibly, absence of SOCS-3 affects sympathetic and/or vagal innervations of the digestive tract. Further investigation is required to test these two hypotheses.
Socs-3 mutants had a larger number of pSTAT3+ hypothalamic cells than Pptn1 mice revealed by immunohistochemistry upon leptin administration, despite having similar leptin sensitivity assessed by leptin-induced body weight loss. This contradiction is only apparent because the immunochemical assay only reveals a subset of leptin sensitive cells (those with large amounts of pSTAT3), whereas not all cells may respond equally well to leptin. The number of poorly versus highly leptin responsive cells might differ between genotypes. Moreover, absence of PTP-1B resulted in an increased number of ARN pSTAT3+ cells under basal conditions, suggesting enhanced basal leptin sensitivity in Ptpn1 and double mutant arcuate nuclei.
Surprisingly, fat depots are not equally affected by combined loss of SOCS-3 and PTP-1B in brain. Indeed, double mutants presented a reduction in visceral fat pads, whereas subcutaneous pads were less affected. Subcutaneous fat is believed to have beneficial effects on glucose tolerance and insulin sensitivity as opposed to visceral fat (49). Therefore, this phenotype in turn may contribute to the enhanced insulin and glucose sensitivity observed in double mutants.
In our study, inactivation of SOCS-3 and PTP-1B was achieved in the whole brain and was not cell-type specific. Peptidic hormone and cytokine effects are not confined to the hypothalamus and leptin, for example, modulates the mesolimbic dopamine system (5,7,9) and long-term depression in the hippocampus (50). Hence, other behaviors than those reported here may be altered in the double mutants. In addition, the JAK/STAT pathway is involved in cell proliferation and SOCS-3 and PTP-1B suppress this pathway. Although we did not observe any gross histological abnormalities in brain of mutant mice, we cannot rule out that inactivation of Socs-3 and Ptpn1 may in turn affect neural development as well as neurogenesis in adulthood (51).
We here provided evidence that abolishing both SOCS-3 and PTP-1B cytokine suppressor activities in brain is beneficial for body weight and glucose homeostasis because of their additive effects for most of the investigated phenotypes. We also found evidence for protein-specific roles and for synergism in the case of body length. Importantly, our study suggests that using a combination of inhibitors for SOCS-3 and PTP-1B may improve therapeutic trials targeting obesity and type 2 diabetes.
This work was supported by National Institutes of Health Grant DK R37 28082 (to J.S.F.) and Grant 2P01DK56116 (to the Neuroanatomy core of the Beth Israel Deaconess Medical Center Division of Endocrinology).
No potential conflicts of interest relevant to this article were reported.
N.B. designed and performed the experiments, analyzed the data, and wrote the manuscript. D.E.M. contributed to data analysis and discussion and reviewed/edited the manuscript. E.M.-F. contributed to experiment design and discussion, reviewed data, and reviewed/edited the manuscript. J.S.F. acted as principal investigator, provided support and contributed to the general outline of the studies, and reviewed data/manuscript.
We thank Kendra K. Bence (University of Pennsylvania), Barbara B. Kahn (Beth Israel Deaconess Medical Center), and Benjamin G. Neel (Ontario Cancer Institute, Canada) for providing the Ptpn1 floxed mice and Akihiko Yoshimura (Kyushu University, Fukuoka, Japan) for providing the Socs-3 floxed mice; the Neuroanatomy core of the BIDMC Division of Endocrinology for help with microtome sectioning; and Deepthi Prasad, Katherine E. Kurgansky, and Donna M. Adams for technical assistance (Beth Israel Deaconess Medical Center).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
- Received April 6, 2010.
- Accepted September 8, 2010.
- © 2010 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.